High-All-Trans Lutein Crystals for Macular Pigment and Visual Function: Formulation Characteristics and Human Intervention Evidence

Nour-Eddine  Ziraoui; Kwame  Mensah; Lerato  Khumalo

doi:10.51699/wbcm8d64

Authors

Nour-Eddine Ziraoui National Laboratory of Medicine LLC, USA
Kwame Mensah National Laboratory of Medicine LLC, USA
Lerato Khumalo National Laboratory of Medicine LLC, USA

DOI:

https://doi.org/10.51699/wbcm8d64

Keywords:

lutein, all-trans lutein, macular pigment optical density, visual function, contrast sensitivity, age-related macular degeneration, crystalline formulation, NVTIA®

Abstract

Macular pigment optical density (MPOD) is a practical measure of lutein accumulation in the human macula. We examined the NVTIA® high-all-trans lutein crystalline material and then placed its analytical profile beside human intervention data on macular pigment and visual performance. Across five process conditions, total lutein was 81.7-82.8%, all-trans lutein 88.8-89.8%, recovery 79.5-80.6%, and cis isomers 10.2-11.2%. Process comparators produced larger changes: removal of MCT-assisted extraction reduced recovery, omission of low-oxygen/light control shifted all-trans lutein from 89.8% to 84.0% and cis isomers from 10.2% to 16.0%, and omission of pre-deoiling caused emulsification during saponification with greater resin-column resistance. Human evidence available through 18 August 2026 included randomized trials and meta-analyses of lutein-containing interventions. MPOD increased in several adult studies and in more recent pediatric and adolescent trials. Contrast sensitivity, glare, photostress recovery, visual acuity, and AMD progression were less uniform across populations and endpoints. The process data identify a chemically consistent starting material; the clinical literature identifies MPOD as a direct tissue-response measure, with visual-performance tests used as separate functional outcomes.

References

[1] P. S. Bernstein et al., “Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease,” Prog. Retin. Eye Res., vol. 50, pp. 34-66, 2016, doi: 10.1016/j.preteyeres.2015.10.003.

[2] S. Richer et al., “Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in atrophic age-related macular degeneration: The Veterans LAST study,” Optometry, vol. 75, no. 4, pp. 216-230, 2004, doi: 10.1016/S1529-1839(04)70049-4.

[3] G. Weigert et al., “Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration,” Invest. Ophthalmol. Vis. Sci., vol. 52, no. 11, pp. 8174-8178, 2011, doi: 10.1167/iovs.11-7522.

[4] L. Ma et al., “Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration,” Ophthalmology, vol. 119, no. 11, pp. 2290-2297, 2012, doi: 10.1016/j.ophtha.2012.06.014.

[5] I. J. Murray, M. Makridaki, R. L. P. van der Veen, D. Carden, N. R. A. Parry, and T. T. J. M. Berendschot, “Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: The CLEAR study,” Invest. Ophthalmol. Vis. Sci., vol. 54, no. 3, pp. 1781-1788, 2013, doi: 10.1167/iovs.12-10715.

[6] Y. M. Huang et al., “Effect of supplemental lutein and zeaxanthin on serum, macular pigmentation, and visual performance in patients with early age-related macular degeneration,” Biomed. Res. Int., vol. 2015, Art. no. 564738, 2015, doi: 10.1155/2015/564738.

[7] N. Machida, M. Kosehira, and N. Kitaichi, “Clinical effects of dietary supplementation of lutein with high bio-accessibility on macular pigment optical density and contrast sensitivity: A randomized double-blind placebo-controlled parallel-group comparison trial,” Nutrients, vol. 12, no. 10, Art. no. 2966, 2020, doi: 10.3390/nu12102966.

[8] L. M. Wilson, S. Tharmarajah, Y. Jia, R. D. Semba, D. A. Schaumberg, and K. A. Robinson, “The effect of lutein/zeaxanthin intake on human macular pigment optical density: A systematic review and meta-analysis,” Adv. Nutr., vol. 12, no. 6, pp. 2244-2254, 2021, doi: 10.1093/advances/nmab071.

[9] B. R. Hammond Jr., L. M. Fletcher, F. Roos, J. Wittwer, and W. Schalch, “A double-blind, placebo-controlled study on the effects of lutein and zeaxanthin on photostress recovery, glare disability, and chromatic contrast,” Invest. Ophthalmol. Vis. Sci., vol. 55, no. 12, pp. 8583-8589, 2014, doi: 10.1167/iovs.14-15573.

[10] R. Parekh, B. R. Hammond Jr., and D. Chandradhara, “Lutein and zeaxanthin supplementation improves dynamic visual and cognitive performance in children: A randomized, double-blind, parallel, placebo-controlled study,” Adv. Ther., vol. 41, no. 4, pp. 1496-1511, 2024, doi: 10.1007/s12325-024-02785-1.

[11] A. L. Lopresti and S. J. Smith, “Supplementation with lutein and zeaxanthin increases macular pigment optical density and cognitive performance in healthy teenagers in a randomized, double-blind, placebo-controlled trial,” Nutr. Res., vol. 152, pp. 132-144, 2026, doi: 10.1016/j.nutres.2026.06.005.

[12] R. Liu, T. Wang, B. Zhang, L. Qin, C. Wu, Q. Li, and L. Ma, “Lutein and zeaxanthin supplementation and association with visual function in age-related macular degeneration,” Invest. Ophthalmol. Vis. Sci., vol. 56, no. 1, pp. 252-258, 2015, doi: 10.1167/iovs.14-15553.

[13] Age-Related Eye Disease Study 2 Research Group, “Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The AREDS2 randomized clinical trial,” JAMA, vol. 309, no. 19, pp. 2005-2015, 2013, doi: 10.1001/jama.2013.4997.

[14] E. J. Johnson, “Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan,” Nutr. Rev., vol. 72, no. 9, pp. 605-612, 2014, doi: 10.1111/nure.12133.

[15] M. Eggersdorfer and A. Wyss, “Carotenoids in human nutrition and health,” Arch. Biochem. Biophys., vol. 652, pp. 18-26, 2018, doi: 10.1016/j.abb.2018.06.001.